Abera Bioscience AB
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience. Our founder and CTO, Prof. Joen Luirink is a world-leading expert on bacterial protein trafficking and membrane transport systems and his vast knowledge in the area provided the basis for Abera’s innovative vaccine delivery platform. Abera’s novel vaccine delivery platform was first developed for the production of difficult-to-express proteins by bacteria. But when we developed the possibility to display antigenic proteins on bacterial surfaces, the idea of exploiting it for vaccine delivery was born. Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Since the start we have collaborated with academia and the biotech industry to develop and refine the platform. A number of experimental vaccines was designed to provide valuable proof of concept for our technology (e.g. against pneumococcal disease, chlamydia, ETEC and tuberculosis). Many collaborations have received significant financial support from EU (Horizon 2020, Eurostars and Eureka), governments and non-profit health organizations. This has enabled us to advance the technology and build our solid foundation of today.
We strongly believe that vaccines are one of the most powerful tools to save lives and increase health globally. Abera is dedicated to the development of novel vaccines and vaccine strategies to meet these ambitions.
Our mission is to develop vaccine candidates based on our novel vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines.